care environment, and data analytics. CONCLUSIONS: The integration of pharmacogenomic testing with real-world studies offers an important opportunity to identify sub-groups of patients for whom treatment is more effective in terms of clinical, and safety outcomes. Alongside resource utilization and cost of care data, this evidence can be used to populate cost-effectiveness and other health economic analyses to inform physician and payer decision-making.
PRM6 ARE YOU COUNTING PRESCRIPTION MEDICATIONS UTILIZATION CORRECTLY?
Athavale AS 
OBJECTIVES:
To evaluate the potential for duplicate counting of prescription medication utilization for products that are billed through medical and prescription claims. METHODS: A retrospective cross-sectional descriptive study was conducted using the 2008 -2011 Mississippi Medicaid data. Medical claims (MCs) with J-codes for injectable medications were identified from MC files. Prescription claims (PCs) for the corresponding beneficiaries were extracted from PC data for all NDCs associated with the J-codes identified. These two sets of claims were stacked to obtain a denominator file. Potential duplicate counts were identified by pairing MCs and PCs for the same beneficiary and drug where the PC service date was within 7 days of the MC service date. The Medicare maximum allowable cost was identified for the J-code in each potential duplicate count situation. Criteria of the MC being 80ϩ% of the maximum allowable cost for one J-code unit and the MC paid amount being 80ϩ% of the corresponding PC paid amount were used to evaluate which pairs might be actual duplicate counts. RESULTS: Out of 1,813,251 claims identified in the denominator file, 1443 drug events were considered to be potential duplicate counts (0.08%). These claims were associated with 849 Medicaid enrollees. For 89% of the pairs, the MC paid amount was 80ϩ% of the allowable J-code unit cost and 37% were 80ϩ% of the corresponding PC paid amount. Using a combination of these criteria, it was estimated that at least 47% of the pairs were likely to be duplicate counts and that a large portion of the other pairs might be duplicate counts. CONCLUSIONS: Researchers need to use caution when counting medication events for products reimbursed as MCs and PCs. The error from over-counting at the population level should be small, but could have significant impact on utilization and adherence estimates for individual patients. BACKGROUND: Numerous assumptions and techniques are associated with performing meta-analysis. While some overall structural guidelines and recommended practices exist, there are very few papers that compare meta-analysis techniques in application. OBJECTIVES: To review primary meta-analysis methods and their assumptions, and apply various meta techniques to data and compare the results. METHODS: There are currently a myriad of meta-analysis techniques available. We started the study with a review of fixed effects models, which is the most basic technique that assumes homogeneity in treatment effect across studies. We then explored random effect models and meta regression. Each of these techniques models treatment heterogeneity. Other more advanced techniques examined included mixed treatment comparisons (MTC) and Bayesian approaches. RESULTS: Estimates of treatment effect differed depending on the meta technique applied. When a fixed effect model was applied to estimate the effect of a vaccination against tuberculosis, the log odds ratio was -0.436 (confidence interval [CI: -0.528, -0.344]). After testing for heterogeneity and fitting a random effects model, the estimate was reduced to -0.741 (CI [-1.12, -0.352]) , and the CI became wider. When covariates were added to the model to explain the heterogeneity, the treatment effect was reduced even further. Additional techniques were applied as well, such as Bayesian MTC. CONCLUSIONS: Results from meta-analysis are sensitive to the studies selected, in addition to the methodology applied. To ensure that proper techniques are used, it is critical to estimate an unbiased outcome.
PRM7 A REVIEW AND APPLIED COMPARISON OF META-ANALYSIS TECHNIQUES

RESEARCH ON METHODS -COST METHODS
PRM8 GENERAL TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS
Carswell C, McWilliams P, Williamson KA, Faulds D Adis, Auckland, New Zealand OBJECTIVES: Economic evaluations of drug therapy are important, but time consuming and costly. Analyses that are easily transferable (i.e. adjustable to a different jurisdiction without completely rebuilding the model) may potentially save time and resources. We aimed to develop a tool to assess and summarize the general transferability of model-based analyses. METHODS: Medline was searched for literature on transferability published between 2002 and June 2011. Existing checklists for economic evaluations were adapted to create a checklist of 16 key factors to assess the general transferability of model-based analyses. This tool was used to score 11 recently published economic evaluations and identify how well specific factors were addressed. RESULTS: Transferability scores of the selected papers ranged from 53-91%, illustrating the wide variability in the quality of reporting. Across all studies, the least well addressed transferability factors included the discussion of the generalizability of the study results (lacking or incomplete in all studies), adequate description of resources and costs employed in the analysis (particularly separate reporting of resource use and unit costs), and adequate descriptions of the method and/or populations used to derive utility values. The best addressed transferability factors included those relating to country, currency and discount rates. Even if studies scored highly overall, it may still be difficult to transfer the findings to a different setting if they failed to report insufficient detail on one or two key parameters. CONCLUSIONS: The general transferability of a model-based economic evaluation from one country or jurisdiction to another can be quickly assessed by the application of a simple checklist of key transferability factors. It is important that authors ensure that they report their economic analysis in a detailed and transparent fashion. NMEs/NBLs, 36% had PE publications, with 81% considering the approval indication and 61% published post-approval. A US context was assessed in 35% of publications. PMF was present in 68% of publications, comprising manufacturers marketing either the NME/NBL, 90%, or a comparator, 10%. Time (meanϮstandard deviation (S.D.)) since FDA approval was 21.9Ϯ8.8 months until ePublication and 15.3Ϯ9.0 months until journal submission. Median and meanϮS.D. QHES score were 78 and 73.3Ϯ16.4, respectively. Publications most often satisfied QHES items regarding uncertainty (5) and incremental analysis (6) (94% each). Justifiying the chosen model (13) and discussing biases (14) were satisfied least often (38% each). The IF-5y (meanϭ 3.46, S.D.ϭ 3.37) was not correlated with QHES score (Pearson rϭ0.095, pϭ0.636). QHES scores were not-significantly different (pϾ0.05) for any study characteristics. CONCLUSIONS: QHES scores indicate PE studies of recent NMEs/NBLs are high quality, although US relevance is imperfect: few publications assessed a US context; some did not consider the approval indication; publication lags delay PE evidence availability; and most publications have PMF.
PRM10 THE BEHAVIORAL ECONOMICS OF THE MINIMALLY IMPORTANT DIFFERENCE
Suh JK, Doctor J USC School of Pharmacy, Los Angeles, CA, USA OBJECTIVES: To study whether the minimally important differences (MIDs) values outcomes based on the behavioral economic theory. METHODS: We studied the behavior of individuals discriminating minimally important differences (MIDs), a method that identifies the change in a health measure necessary for a patient to discriminate an improvement. The behavioral theory predicts that discrimination of a quantity is governed by Weber's Law: If a quantity is increased by some factor, A160 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
